Drug intelligence / Profile preview

TT-601

Development stage: Discontinued
Lead developer: OPKO Health
Modality: Small Molecules

Overview

**TT-601** is a discontinued small molecule drug candidate that acts as a potent and selective ligand for a novel nuclear receptor target. It was initially developed by Eli Lilly & Co. for potential use in treating osteoarthritis pain by modulating the activity of this target. The program was later acquired by Transition Therapeutics Inc., but development has been discontinued, with no further clinical advancement reported in nervous system diseases or skin and musculoskeletal disorders.[7][10][13]

Beyond the preview

Go deeper on TT-601.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TT-601.

Explore the full profile